Comerica Bank Decreases Stake in Bristol Myers Squibb Company $BMY

Key Points

• Comerica Bank trimmed its stake in Bristol Myers Squibb by 3.8% in Q4, selling 25,379 shares and finishing the quarter with 637,744 shares worth about $34.4 million.
• Analysts have lifted price targets to roughly $60 with a consensus target of $61.31, though the street rating remains a "Hold" (8 Buy, 10 Hold, 1 Sell).
• Bristol Myers missed Q4 EPS ($1.26 vs. $1.65 expected) but beat revenue, set FY2026 guidance of 6.05–6.35 EPS, and announced a quarterly dividend of $0.63 (4.4% yield; ex-dividend April 2).

Comerica Bank reduced its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 637,744 shares of the biopharmaceutical company's stock after selling 25,379 shares during the period. Comerica Bank's holdings in Bristol Myers Squibb were worth $34,400,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth about $25,000. Physician Wealth Advisors Inc. raised its position in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 202 shares during the period. Harbor Capital Advisors Inc. raised its position in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 313 shares during the period. KERR FINANCIAL PLANNING Corp purchased a new stake in Bristol Myers Squibb during the third quarter valued at approximately $35,000. Finally, JPL Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the third quarter valued at approximately $36,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on BMY shares. Leerink Partners upped their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research report on Tuesday, January 13th. Wells Fargo & Company restated an "outperform" rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. HSBC upped their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a research report on Tuesday, March 17th. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 price objective on the stock. Finally, Scotiabank restated a "sector perform" rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus target price of $61.31.

Bristol Myers Squibb Stock Down 1.4%

Shares of NYSE:BMY opened at $57.86 on Tuesday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock has a market cap of $118.13 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The business's 50 day moving average is $59.63 and its 200 day moving average is $54.31. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm's quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.28 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is currently 73.04%.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.